The Medicines and Healthcare products Regulatory Agency (MHRA) of Great Britain has officially authorized a new drug plozasiran, which will be marketed under the trade name Redemplo. The decision was made on October 19, 2026, and concerns the treatment of adult patients suffering from familial chylomicronemia syndrome. This disease is a rare genetic disorder in which the body is unable to effectively break down fats, leading to abnormally high levels of triglycerides in the blood. This condition can cause serious complications, including acute pancreatitis, and requires specialized medical management. The approval of plozasiran opens new therapeutic possibilities for patients who previously had limited treatment options for this rare syndrome. The drug will add to the list of medications available in Great Britain for combating lipid metabolism disorders. The MHRA is the national regulator responsible for assessing the safety, efficacy, and quality of medicinal products and medical devices in the country. Authorization of drugs by this agency means they have undergone the necessary clinical trials and meet established standards for use in clinical practice on the territory of Great Britain.